New Capital Healthcare Disruptors Fund GBP Unhedged Acc.

Reference Data

ISIN IE00028OZXY1
Valor Number
Bloomberg Global ID
Fund Name New Capital Healthcare Disruptors Fund GBP Unhedged Acc.
Fund Provider EFG - New Capital EFG Asset Management (UK) Ltd
Park House, 116 Park Street
London, W1K 6AP, United Kingdom
Phone: +44 207 173 8011
E-Mail: enquiries@newcapital.com
Fund Provider EFG - New Capital
Representative in Switzerland CACEIS (Switzerland) SA
Nyon
Phone: +41 22 360 94 00
Distributor(s) EFG Bank AG
Zürich
Asset Class Bonds
EFC Category
Distribution Policy Accumulation
Home Country Ireland
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the Sub-Fund is to achieve capital appreciation through investment in a portfolio of equity securities. In order to achieve its investment objective, the Sub-Fund will invest in equities issued by US companies listed or traded on Recognised Markets in the United States such as the NASDAQ, the New York Stock Exchange, the American Stock Exchange, the Chicago Mercantile Exchange and the Chicago Board of Trade across all market capitalizations. The Sub-Fund may invest up to a maximum of 20% of the Net Asset Value in non-US companies including up to 10% of its assets in securities of emerging market issuers.
Peculiarities

Fund Prices

Current Price * 95.98 GBP 03.04.2025
Previous Price * 100.53 GBP 02.04.2025
52 Week High * 120.01 GBP 05.02.2025
52 Week Low * 95.98 GBP 03.04.2025
NAV * 95.98 GBP 03.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 42,816,499
Unit/Share Assets *** 197,752
Trading Information SIX

Performance

YTD Performance -11.56% 31.12.2024
03.04.2025
YTD Performance (in CHF) -12.39% 31.12.2024
03.04.2025
1 month -11.11% 03.03.2025
03.04.2025
3 months -13.77% 03.01.2025
03.04.2025
6 months -10.18% 03.10.2024
03.04.2025
1 year -11.03% 03.04.2024
03.04.2025
2 years +0.96% 03.04.2023
03.04.2025
3 years -6.13% 04.04.2022
03.04.2025
5 years -15.00% 26.07.2021
03.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE ADR 5.78%
Eli Lilly and Co 5.43%
Natera Inc 5.25%
Veeva Systems Inc Class A 4.97%
Doximity Inc Class A 4.62%
Halozyme Therapeutics Inc 4.60%
Intuitive Surgical Inc 4.56%
Alnylam Pharmaceuticals Inc 4.31%
Stryker Corp 4.30%
IDEXX Laboratories Inc 3.96%
Last data update 31.03.2025

Cost / Risk

TER 0.01%
TER date 30.06.2023
Performance Fee ***
PTR
Max. Management Fee *** 0.75%
Ongoing Charges *** 1.02%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)